Document Detail

Use of glycoprotein IIb/IIIa inhibitors in invasively-treated patients with non-ST elevation acute coronary syndrome.
MedLine Citation:
PMID:  16645379     Owner:  NLM     Status:  MEDLINE    
Background In patients with non-ST elevation acute coronary syndrome (NST-ACS) that is treated invasively, glycoprotein (GP) IIb/IIIa inhibitors can be used either as upstream treatment in a coronary care unit or as downstream provisional treatment in selected patients who are undergoing percutaneous coronary intervention (PCI). The relative advantage of either strategy is unknown. The purpose of this study was to assess 30-day outcome of patients enrolled in a prospective NST-ACS registry and treated invasively with either of these two therapeutic strategies. Methods Patients treated invasively (coronary arteriography within 4 days of admission), in the prospective registry ROSAI-2, were divided into two groups according to the upstream use of GPIIb/IIIa inhibitors (n = 241), or not (n = 548). In the latter group, 76 (14%) patients received GPIIb/IIIa in association with a PCI procedure. Clinical and angiographic characteristics as well as in-hospital and 30-day outcome of these two groups of patients were compared. Results The two groups were similar with respect to age, sex, presence of hypertension, diabetes, number of PCI procedures. However, patients treated with upstream GPllb/llla blockers had more frequently ST-segment depression (P = 0.002), a high TIMI risk score (P = 0.01) and were more frequently admitted to centres with Cath Lab facilities (P = 0.001). At 30-day follow-up, the composite of death, acute myocardial infarction and stroke, as well as major bleeding, was not significantly different between the two groups, although it occurred more frequently in patients who received upstream GPIIb/IIIa blockers (9.5% versus 5.7% and 1.7% versus 0.2%, respectively). By multivariate analysis, diabetes [odds ratio (OR) = 2.22, 95% confidence interval (CI) = 1.2-4.09] and a diagnosis on admission of non-Q-wave myocardial infarction (OR = 2.0, 95% Cl = 1.10-3.6) were independently related to outcome. No additional risk or benefit was related to upstream GPIIb/IIIa inhibitor treatment (OR = 1.5, 95% Cl = 0.84-2.68). Conclusions Among invasively-treated patients with NST-ACS, upstream treatment with GPIIb/IIIa inhibitors was used in those with a higher clinical risk profile, whereas downstream treatment was reserved for a limited number of patients undergoing PCI. Thirty-day outcome was similar in the two groups, irrespective of the treatment strategy used.
Stefano De Servi; Matteo Mariani; Pietro Vandoni; Antonio Dellavalle; Alessandro Politi; Fabrizio Poletti; Erminio Bonizzoni; Mario Leoncinie;
Related Documents :
20062919 - Clopidogrel response status assessed with multiplate point-of-care analysis and the inc...
15148279 - Post-sirolimus-eluting stent restenosis treated with repeat percutaneous intervention: ...
18030199 - Evaluation of acute myocardial infarction with late enhancement pattern on mri compared...
20671639 - Safety and efficacy of directional atherectomy for the treatment of in-stent restenosis...
12384629 - Drug-eluting stents: clinical experiences and perspectives.
19018239 - Impact of direct sirolimus-eluting stent implantation on the early systemic inflammator...
22599359 - Clinical characteristics and corticosteroid treatment of acute eosinophilic pneumonia.
952569 - Reduction of early occlusions in the high risk peripheral saphenous vein graft.
21431319 - Non-cutting setons for progressive migration of complex fistula tracts: a new spin on a...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of cardiovascular medicine (Hagerstown, Md.)     Volume:  7     ISSN:  1558-2027     ISO Abbreviation:  J Cardiovasc Med (Hagerstown)     Publication Date:  2006 Mar 
Date Detail:
Created Date:  2006-05-02     Completed Date:  2006-05-25     Revised Date:  2013-05-24    
Medline Journal Info:
Nlm Unique ID:  101259752     Medline TA:  J Cardiovasc Med (Hagerstown)     Country:  United States    
Other Details:
Languages:  eng     Pagination:  159-65     Citation Subset:  IM    
Unita' Operativa di Cardiologia, Ospedale Civile di Legnano, Legnano, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angina, Unstable / drug therapy*,  therapy
Angioplasty, Balloon, Coronary*
Antibodies, Monoclonal / therapeutic use
Combined Modality Therapy
Coronary Angiography
Immunoglobulin Fab Fragments / therapeutic use
Middle Aged
Multicenter Studies as Topic
Multivariate Analysis
Myocardial Infarction / drug therapy*,  mortality,  therapy
Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors*
Tyrosine / analogs & derivatives*,  therapeutic use
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Immunoglobulin Fab Fragments; 0/Platelet Glycoprotein GPIIb-IIIa Complex; 144494-65-5/tirofiban; 55520-40-6/Tyrosine; X85G7936GV/abciximab
Comment In:
J Cardiovasc Med (Hagerstown). 2006 Mar;7(3):166-8   [PMID:  16645380 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The Titan can help titin: from micro to macro myocardial elasticity.
Next Document:  Performing versus deferring coronary angioplasty based on functional evaluation of vessel stenosis b...